ArticleThe European respiratory journal2019
IL-22 and its receptors are increased in human and experimental COPD and contribute to pathogenesis.
Article in The European respiratory journal, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed, 1 synthesis or guideline pooled it, 80 citations in OpenAlex.
- Chronic Inflammation as the Underlying Mechanism of the Development of Lung Diseases in Psoriasis: A Systematic Review.International journal of molecular sciences · 2022Pooled it
- Erythromycin inhibits the differentiation of NCRJournal of thoracic disease · 2026Article
- γδ T Cells at the Crossroads of Tuberculosis and COPD: From Early Immunity to Tissue Remodeling.International journal of molecular sciences · 2026Review
- Fungal exposure exacerbates allergen-driven asthma in a two-hit mouse model.Respiratory research · 2026Article
- Vaping versus smoking: a quest for long-term impact in a mouse model.BMC pulmonary medicine · 2025Article
- Baicalin restores innate lymphoid immune imbalance during exacerbation of COPD.Immunologic research · 2025Article
- Vitronectin regulates lung tissue remodeling and emphysema in chronic obstructive pulmonary disease.Molecular therapy : the journal of the American Society of Gene Therapy · 2025Article
- Exploring the pathogenesis and clinical implications of asthma, chronic obstructive pulmonary disease (COPD), and asthma-COPD overlap (ACO): a narrative review.Frontiers in medicine · 2025Review
- Fezakinumab Alleviates Cigarette Smoke-Induced COPD by Suppressing the JAK1/STAT3 Pathway in Mice.Canadian respiratory journal · 2025Article
- Relationship between lung function impairment, clinical characteristics and systemic inflammation based on a large-scale population screening.Frontiers in medicine · 2025Article
- CD4Frontiers in immunology · 2025Review
- Knowledge mapping and research trends of IL-22 from 2014 to 2023: A bibliometric analysis.Human vaccines & immunotherapeutics · 2024Article
- I don't know about you, but I'm feeling IL-22.Cytokine & growth factor reviews · 2024Review
- In Situ Expression of YakVeterinary sciences · 2024Article
- IL-22: A key inflammatory mediator as a biomarker and potential therapeutic target for lung cancer.Heliyon · 2024Review
- Development and validation of a mortality risk prediction model for chronic obstructive pulmonary disease: a cross-sectional study using probabilistic graphical modelling.EClinicalMedicine · 2024Article
- Review
- Endotypes of severe neutrophilic and eosinophilic asthma from multi-omics integration of U-BIOPRED sputum samples.Clinical and translational medicine · 2024Article
- Identification of Serum Interleukin-22 as Novel Biomarker in Pulmonary Hypertension: A Translational Study.International journal of molecular sciences · 2024Article
- IL-22 Binding Protein/IL-22 Axis in Regulating Acute Lung Injury.The American journal of pathology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors at 7 institutions in 5 countries.
Funding
Abstract
Chronic obstructive pulmonary disease (COPD) is the third leading cause of morbidity and death globally. The lack of effective treatments results from an incomplete understanding of the underlying mechanisms driving COPD pathogenesis.Interleukin (IL)-22 has been implicated in airway inflammation and is increased in COPD patients. However, its roles in the pathogenesis of COPD is poorly understood. Here, we investigated the role of IL-22 in human COPD and in cigarette smoke (CS)-induced experimental COPD.IL-22 and IL-22 receptor mRNA expression and protein levels were increased in COPD patients compared to healthy smoking or non-smoking controls. IL-22 and IL-22 receptor levels were increased in the lungs of mice with experimental COPD compared to controls and the cellular source of IL-22 included CD4
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.